Single-use Bioprocessing Market Key Findings Focus on User Experience -

The global single-use bioprocessing market was valued at USD 27.94 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 16.24% from 2024 to 2030. The adoption of single-use bioprocessing technology is driven by the growing demand for biopharmaceuticals over the past few years, along with an increase in investments for the development of biologics, such as monoclonal antibodies, vaccines, recombinant proteins, and others. Furthermore, benefits pertaining to the use of single-use technology, such as significant reduction in costs and time required for operations & facility construction have supported the implementation of single-use systems in the bioprocessing sector.

The COVID-19 pandemic has generated new growth opportunities for key stakeholders in the industry. Key biopharmaceutical players can leverage the opportunity by expanding their COVID-19-related product offerings by scaling up their production facilities with the implementation of single-use bioprocessing equipment. A significant number of biopharmaceutical companies are actively involved in the development & production of COVID-19 vaccines. These programs are majorly based on single-use technologies as these systems are flexible, cost-effective, and reduce the risk of cross-contamination.

Such an ongoing and continuous increase in the adoption of these bioprocessing systems due to the COVID-19 pandemic is anticipated to drive industry growth. The commercial success of biopharmaceuticals has led single-use manufacturers to expand their production facilities globally. Capacity expansion projects have been a part of many manufacturers’ multi-year plans, to leverage a global reach and a broader customer base. For instance, in December 2020, Merck KGaA invested over USD 42 million to broaden its existing manufacturing facilities in Danvers, Massachusetts, and Jaffrey, New Hampshire, U.S.

This expansion was aimed at enhancing the company’s single-use assembly operations along with other product portfolios. Furthermore, with the rising focus on the development of regenerative medicine, such as cell and gene therapies, increased success of clinical trials, and enhanced rate of regulatory approvals, demand for commercialization of these products is expected to grow in the near future. In addition, owing to the increasing outsourcing activities in biopharmaceutical manufacturing, CMOs are adopting single-use systems for maintaining highly dynamic and frequently changing product portfolios.

Consequently, the extensive implementation of single-use systems in CMOs across the globe is likely to boost industry growth. For instance, in July 2021, Pall Corp. signed a contract with Exothera S.A., a CDMO, to establish a manufacturing space using Allegro STR single-use bioreactors and other technologies. Although innovations in single-use technology are the current trend for the bioprocessing industry, the technology has still not completely displaced stainless steel reusable systems. High-volume biopharmaceutical product manufacturers continue to fixate on the multi-use system due to their feasibility at large scales. This represents a significant challenge for the industry’s growth.

Get a preview of the latest developments in the Global Single-use Bioprocessing Market! Download your FREE sample PDF today and explore key data and trends

Regional Insights

North America held the largest revenue share of more than 34.19% in 2023, which can be attributed to the presence of an established pharmaceutical and biomanufacturing industry in the region as well as a high extent of R&D activities. Similarly, the demand for single-use bioprocessing equipment is also driven by an increasing focus on vaccine production to aid in disease prevention measures in the region. Moreover, the presence of the Bio-process System Alliance (BPSA) in North America, which aims at advancing the adoption of single-use technologies, is expected to further drive the sales of disposable systems in the region.

The Asia Pacific region is expected to grow at the fastest rate over the forecast period. The region’s growing bioprocessing market has resulted in multiple investments from several global companies. These investments assist in serving the key companies to create a regional presence and take advantage of the untapped avenues. Furthermore, the increasing interest of contract service providers to develop their base in the Asia Pacific, coupled with the trend of implementation of disposables in CMOs, acts as a catalyst for continued investments by local as well as global companies. For instance, in September 2021, Singapore witnessed the expansion of Lonza’s drug development facility.

Key Single-use Bioprocessing Company Insights

The market is witnessing several strategic initiatives such as product launches, expansions adopted by key players to increase their reach in the market and to maintain their industry presence. These developments also enhance the availability of their products in diverse geographical areas.

Key Single-use Bioprocessing Companies:

The following are the leading companies in the single-use bioprocessing market. These companies collectively hold the largest market share and dictate industry trends. Financials, strategy maps & products of these single-use bioprocessing companies are analyzed to map the supply network.